» Articles » PMID: 21446023

Neurologic Features and Genotype-phenotype Correlation in Wolfram Syndrome

Overview
Journal Ann Neurol
Specialty Neurology
Date 2011 Mar 30
PMID 21446023
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Wolfram syndrome (WS) is a rare neurodegenerative disorder characterized by juvenile-onset diabetes mellitus and optic atrophy. Our aim was to describe the nature and the frequency of the neurologic manifestations, which had been poorly studied until now.

Methods: We performed a detailed clinical study with genotype-phenotype correlation in a series of 59 patients with WS.

Results: The onset of neurologic symptoms, with a median age of 15 years, was much earlier than previously reported. Cognitive impairment, which was not frequent in previous reports, was observed in 32% of patients with neurologic signs. Like epilepsy, it was mainly found in patients who developed neurologic signs before 15 years of age. In contrast to previous series, we also found malformations of cortical development on magnetic resonance imaging in epileptic children and white matter involvement, including diffuse leukoencephalopathy, in adult patients. We identified 109 mutated alleles corresponding to 56 different mutations of the WFS1 gene, among which 10 were novel. Homozygosity or compound heterozygosity for missense mutation does not seem to influence the age of onset and the occurrence of neurologic complications. However, an interesting point concerns a possible correlation between the location of the mutations and the development of the neurologic manifestations.

Interpretation: This series concerns the largest cohort of WS patients reported to date. It illustrates the wide variety of neurologic signs in this syndrome and the necessity of rapid therapeutic coverage to improve the prognosis.

Citing Articles

Sodium valproate, a potential repurposed treatment for the neurodegeneration in Wolfram syndrome (TREATWOLFRAM): trial protocol for a pivotal multicentre, randomised double-blind controlled trial.

Dias R, Brock K, Hu K, Gupta R, Martin U, Peet A BMJ Open. 2025; 15(2):e091495.

PMID: 40010822 PMC: 11865774. DOI: 10.1136/bmjopen-2024-091495.


Beyond Wolfram Syndrome 1: The Gene's Role in Alzheimer's Disease and Sleep Disorders.

Caruso V, Rigoli L Biomolecules. 2024; 14(11).

PMID: 39595565 PMC: 11591713. DOI: 10.3390/biom14111389.


A WFS1 variant disrupting acceptor splice site uncovers the impact of alternative splicing on beta cell apoptosis in a patient with Wolfram syndrome.

Chimienti R, Torchio S, Siracusano G, Zamarian V, Monaco L, Lombardo M Diabetologia. 2024; 68(1):128-151.

PMID: 39520565 PMC: 11663190. DOI: 10.1007/s00125-024-06307-0.


Insights from a Wolfram syndrome cohort: clinical and molecular findings from a specialized diabetes reference center.

Lopes C, Goncalves G, Paulino M, Esquiaveto-Aun A, de Mello M, Pavin E Arch Endocrinol Metab. 2024; 68:e240091.

PMID: 39420940 PMC: 11460961. DOI: 10.20945/2359-4292-2024-0091.


Wolfram Syndrome 1: A Neuropsychiatric Perspective on a Rare Disease.

Caruso V, Raia A, Rigoli L Genes (Basel). 2024; 15(8).

PMID: 39202345 PMC: 11353439. DOI: 10.3390/genes15080984.